A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know
Sheena executed 9,150 shares under a pre-established trading plan adopted in December 2025.
Overview
Jonathan Sheena, a co-founder of Natera, Inc. (NASDAQ:NTRA), sold 9,150 shares of common stock at $315.66 per share on August 7, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($315.66); post-transaction value based on the August 7 market close ($322.10).
Details
Natera is a leading global diagnostics company with a market capitalization of $46.1 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the molecular diagnostics sector. The company's competitive advantage derives from its proprietary testing platforms and extensive clinical validation data, enabling it to address critical unmet needs in prenatal, carrier, and reproductive health screening. Despite current net losses, Natera's substantial revenue base and market valuation reflect investor confidence in its growth trajectory and the expanding addressable market for non-invasive genetic testing.
Source
Originally published at www.fool.com.